---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/45052105.md"
description: "$Addex Therapeutics(ADXN.US) surged +83% on Thursday, with trading volume over 70 times the usual average. The catalyst comes from Neurosterix, which was spun off by Addex in 2024: the latter completed a $105mn Series B financing round. Its lead pipeline candidate NTX-253 has completed Phase I trials, and the funds will be used to advance Phase II. Addex did not participate in this round but still holds an 8.5% stake, valued at approximately $18.6mn based on the current valuation. $Addex Therapeutics(ADXN.US) has a total of only ~1.2mn ADSs outstanding; at $5.29, its market cap is under $7mn. A single equity holding in its portfolio is worth more than double that market cap, indicating the market is revaluing its private stakes. However, as non-listed equities lack liquidity and cannot be quickly converted to cash, a significant portion of the rally is driven by sentiment."
datetime: "2026-11-13T08:59:41.000Z"
locales:
  - [en](https://longbridge.com/en/topics/45052105.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/45052105.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/45052105.md)
author: "[Dimoo](https://longbridge.com/en/profiles/26968366.md)"
generator: "portal-rs"
---

# $Addex Therapeutics(ADXN.US) surged +83% on Thursd…


### Related Stocks

- [ADXN.US](https://longbridge.com/en/quote/ADXN.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**